Phase 2 Triple Negative Clinical Trials
17 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–17 of 17 trials
Recruiting
Phase 2
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
Triple Negative Breast Neoplasms
Universitaire Ziekenhuizen KU Leuven53 enrolled6 locationsNCT06365788
Recruiting
Phase 2
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer
Triple Negative Breast Cancer (TNBC), Early Setting
Universitaire Ziekenhuizen KU Leuven356 enrolled10 locationsNCT06831955
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 1Phase 2
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
BreastCancerMetastatic+2 more
University of Southern California65 enrolled3 locationsNCT04333706
Recruiting
Phase 2
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
Breast CancerBreast Cancer Stage IIBreast Cancer Invasive+2 more
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's40 enrolled2 locationsNCT07188246
Recruiting
Phase 2
A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
Triple Negative Breast Cancer MetastaticMelanoma MetastaticColorectal Cancer Metastatic
Fudan University95 enrolled1 locationNCT06889610
Recruiting
Phase 2
Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery
Triple Negative Breast Neoplasms
UNICANCER220 enrolled20 locationsNCT05973864
Recruiting
Phase 2
IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma
Metastatic Endocrine RefractoryTriple Negative Invasive Lobular Carcinoma
M.D. Anderson Cancer Center29 enrolled1 locationNCT07229417
Recruiting
Phase 1Phase 2
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Triple Negative Locally Advanced Non-resectable Breast Cancer
Marengo Therapeutics, Inc.50 enrolled8 locationsNCT06827613
Recruiting
Phase 2
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
Triple Negative Breast Cancer Metastatic
IFOM ETS - The AIRC Institute of Molecular Oncology37 enrolled6 locationsNCT05582538
Recruiting
Phase 1Phase 2
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting
Phase 2
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Triple Negative Breast Neoplasms
Okayama University23 enrolled3 locationsNCT05485766
Recruiting
Phase 1Phase 2
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
Breast CancerBreast Cancer MetastaticBreast Carcinoma+1 more
Essen Biotech85 enrolled1 locationNCT06532812
Recruiting
Phase 2
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Early Small (cT1N0) Triple Negative Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris200 enrolled3 locationsNCT05215106
Recruiting
Phase 2
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
Triple Negative Breast Neoplasms
Hunan Cancer Hospital53 enrolled1 locationNCT06385990
Completed
Phase 2
BCT 1702 (CHARIOT): Patients with high-risk primary triple negative breast cancer who have had anthracycline-based chemotherapy will receive Ipilimumab and Nivolumab with weekly paclitaxel, followed by definitive surgery and further treatment with Nivolumab to evaluate the safety, feasibility and efficacy of this treatment.
Primary triple negative breast cancer
Breast Cancer Trials33 enrolled13 locationsACTRN12617000651381
Terminated
Phase 2
A Single Arm Phase II Study of the Efficacy of Tamoxifen in Triple Negative (oestrogen receptor alpha negative, progesterone receptor negative, HER-2 negative) but Oestrogen Receptor Beta Positive Metastatic Breast Cancer
Triple Negative Metastatic Breast Cancer
Australia and New Zealand Breast Cancer Trials Group66 enrolled1 locationACTRN12610000506099